Two of the 28 patients to receive the new treatment in a new study experienced a rebound, whereas none of the 102 patients receiving the traditional treatment did.
Interestingly, the same remained the case for COVID-negative patients with COVID-like symptoms, underscoring the need for more research into the effects of other illnesses.